Submitted by Anonymous (not verified) on 9 January 2026 - 10:35
Human medicines European public assessment report (EPAR): Rimmyrah, ranibizumab, Date of authorisation: 05/01/2024, Revision: 4, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Rimmyrah, ranibizumab, Date of authorisation: 05/01/2024, Revision: 4, Status: Authorised